Carlo Abatini

Dr. Carlo Abatini


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CACarlo Abatini
Carlo Abatini
LBLorenzo Barberis
Lorenzo Barberis
CLClaudio Lodoli
Claudio Lodoli
Federica FerracciFederica Ferracci
Federica Ferracci
ELEnrico De Lorenzis
Enrico De Lorenzis
FSFrancesco Santullo
Francesco Santullo
Background: RPS are rare tumors requiring complex surgery. The impact of postoperative complications on long-term outcomes is still debated. This study aimed to identify predictors of severe complications and assess their influence on overall survival (OS) and disease-free survival (DFS). Methods: We retrospectively analyzed 61 patients who underwent curative surgery for primary RPS between 2013 and 2023 at a tertiary cancer center. Patients with pelvic or recurrent sarcomas were excluded. Severe complications were defined as Clavien–Dindo (CD) grade ≥ 3A. Cox regression and Fine–Gray competing risk models were used for OS and DFS, respectively. Sarculator and P-POSSUM scores were included in multivariable models. Results: Severe complications occurred in 14.8% of patients; 30-day mortality was 1.6%. Predictive factors for complications included longer operative time, gastric resection, intraoperative complications, and transfusions. In multivariable analysis, Sarculator was significantly associated with both DFS (HR 0.97; p = 0.004) and OS (HR 0.97; p = 0.008). The P-POSSUM mortality score predicted OS (HR 1.12; p = 0.002). Severe complications were not independently associated with DFS or OS. Conclusions: In this cohort, severe complications did not impact long-term oncological outcomes. Prognostic tools such as Sarculator and P-POSSUM may enhance risk stratification in RPS surgery. Prospective validation is warranted.

Verified
Journal Article
Open access
PDF file
COCecilia Orsini
Cecilia Orsini
MAMatteo Aulicino
Matteo Aulicino
GDGiorgio D'Annibale
Giorgio D'Annibale
MCMarianna Cantelmo
Marianna Cantelmo
SASara Totaro Aprile
Sara Totaro Aprile
FSFrancesco Santullo
Francesco Santullo
Background: Peritoneal metastases from gastric cancer (GCPM) represent a significant clinical challenge in terms of therapeutic options and prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated promising survival benefits within a multimodal approach, particularly in carefully selected patients. Methods: This retrospective single-center study evaluated outcomes in patients with synchronous GCPM treated with CRS + HIPEC following neoadjuvant chemotherapy. The primary endpoints included overall survival (OS), disease-free survival (DFS), and identification of prognostic factors associated with poor outcomes. Additionally, we sought to characterize patients achieving long-term survival (OS ≥ 24 months). Results: The median OS and DFS were 18 and 13 months, respectively. A peritoneal cancer index (PCI) ≥ 7 and major postoperative complications were independently associated with reduced survival. Recurrence was significantly linked to PCI ≥ 7 and signet ring cell histology. Stratification by survival outcome identified PCI ≥ 7 as the only statistically significant variable differentiating average- and long-survival groups. Moreover, elevated PCI was independently associated with a higher incidence of major postoperative complications. Conclusions: CRS + HIPEC may offer a survival advantage over the use of systemic therapy exclusively in appropriately selected patients, particularly those with limited peritoneal disease burden. These results underscore the importance of accurate patient selection to balance surgical risks and maximize oncological benefits in the treatment of GCPM.

3 July 2026 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
MAMatteo Aulicino
Matteo Aulicino
CACarlo Abatini
Carlo Abatini
CLClaudio Lodoli
Claudio Lodoli
GDGiorgio D’ANnibale
Giorgio D’ANnibale
LBLorenzo Barberis
Lorenzo Barberis
FSFrancesco Santullo
Francesco Santullo

14 May 2026 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
MAMatteo Aulicino
Matteo Aulicino
CACarlo Abatini
Carlo Abatini
CLClaudio Lodoli
Claudio Lodoli
GDGiorgio D’ANnibale
Giorgio D’ANnibale
LBLorenzo Barberis
Lorenzo Barberis
FSFrancesco Santullo
Francesco Santullo

14 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MAMatteo Aulicino
Matteo Aulicino
VTVincenzo Tondolo
Vincenzo Tondolo
CACarlo Abatini
Carlo Abatini
GDGiorgio D’Annibale
Giorgio D’Annibale
LBLorenzo Barberis
Lorenzo Barberis
FSFrancesco Santullo
Francesco Santullo
Background: Minimally invasive surgery (MIS) is increasingly implemented for cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies (PSM). This systematic review and meta-analysis compared minimally invasive CRS/HIPEC (M-CRS/HIPEC) and open CRS/HIPEC (O-CRS/HIPEC) in terms of perioperative, postoperative, and long-term oncological outcomes. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and the Cochrane Library were searched for comparative studies of M-CRS/HIPEC versus O-CRS/HIPEC in adult patients. Risk of bias was assessed using the Newcastle–Ottawa Scale and RoB 2.0. Pooled relative risks (RR) for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes were calculated with 95% confidence intervals (CI). Sensitivity analyses were performed to assess the potential influence of disease burden and primary tumor heterogeneity. Results: Twenty-one studies (1 randomized controlled trial and 20 retrospective cohorts) including 1184 patients (452 M-CRS/HIPEC and 732 O-CRS/HIPEC) were analyzed. Operative time did not differ between groups (SMD = 0.195; p = 0.667). Most cytoreductive procedures were comparable, although small bowel resections were less frequent with M-CRS/HIPEC (RR = 0.537; p = 0.018). The minimally invasive approach achieved higher CC0 rates (RR = 1.053; p = 0.045), with lower blood loss (SMD = −1.838; p < 0.001) and fewer transfusions (RR = 0.588; p = 0.002). Postoperative recovery favored M-CRS/HIPEC, with earlier return of bowel function and resumption of oral intake, shorter hospital stay, fewer readmissions, and earlier chemotherapy resumption (all p < 0.05). Overall and major morbidity were reduced, while postoperative mortality and 1-, 3-, and 5-year disease-free and overall survival did not differ significantly between groups. In the disease burden-restricted sensitivity analysis, differences in small bowel resection, CC0 rate, and 90-day readmission were no longer statistically significant, whereas the main perioperative and recovery benefits persisted. No significant differences in DFS or OS were identified in the additional sensitivity analyses at the evaluable time points. Conclusions: This meta-analysis supports a selective, expertise-driven use of M-CRS/HIPEC, offering perioperative and recovery advantages without significant differences in cytoreductive adequacy or long-term outcomes in appropriately selected patients.

8 May 2026
Verified
Journal Article
Closed access
MAMatteo Aulicino
Matteo Aulicino
CACarlo Abatini
Carlo Abatini
CLClaudio Lodoli
Claudio Lodoli
GDGiorgio D'ANnibale
Giorgio D'ANnibale
LBLorenzo Barberis
Lorenzo Barberis
FSFrancesco Santullo
Francesco Santullo